RU2005114018A - Эпотилон d+фторурацил/гемцитабин - Google Patents
Эпотилон d+фторурацил/гемцитабин Download PDFInfo
- Publication number
- RU2005114018A RU2005114018A RU2005114018/14A RU2005114018A RU2005114018A RU 2005114018 A RU2005114018 A RU 2005114018A RU 2005114018/14 A RU2005114018/14 A RU 2005114018/14A RU 2005114018 A RU2005114018 A RU 2005114018A RU 2005114018 A RU2005114018 A RU 2005114018A
- Authority
- RU
- Russia
- Prior art keywords
- epothilone
- dehydroepotilon
- group
- combination
- epothilones
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Claims (14)
1. Способ лечения гиперпролиферативных заболеваний, который включает введение пациенту, нуждающемуся в таком лечении, комбинации одного или нескольких эпотилонов и одного или нескольких аналогов нуклеозидов.
2. Способ по п. 1, в котором один или несколько эпотилонов и один или несколько аналогов нуклеозидов вводятся одновременно.
3. Способ по п. 2, в котором эпотилон выбирают из группы, состоящей из эпотилона B, эпотилона D, 21-гидроксиэпотилона B, 21-гидроксиэпотилона D, 21-аминоэпотилона B, 21-аминоэпотилона D, азаэпотилона B, азаэпотилона D, 9,10-дегидроэпотилона B, 9,10-дегидроэпотилона D, 26-трифтор-9,10-дегидроэпотилона B и 26-трифтор-9,10-дегидроэпотилона D.
4. Способ по п. 2, в котором аналог нуклеозида выбирают из группы, состоящей из азацитидина, кладрибина, цитарабина, флоксуридина, флударабина фосфата, 5-фторурацила, гемцитабина, пентостатина, урамустина и 5'-дезокси-5-фтор-N-[(пентилокси)карбонил]-цитидина.
5. Способ по п. 2, в котором эпотилоном является эпотилон D и аналог нуклеозида выбирают из группы, состоящей из 5-фторурацила и 5'-дезокси-5-фтор-N-[(пентилокси)карбонил]-цитидина.
6. Способ по п. 2, в котором эпотилон используют в дозах от примерно 1 мг/м2 до примерно 200 мг/м2.
7. Способ по п. 1, в котором сначала вводится один или несколько эпотилонов, а затем - один или несколько аналогов нуклеозидов.
8. Способ по п. 1, в котором сначала вводится один или несколько аналогов нуклеозида, а затем - один или несколько эпотилонов.
9. Способ по п. 1, в котором указанной гиперпролиферацией является злокачественная опухоль, выбранная из группы, состоящей из рака толстой кишки, рака молочной железы и немелкоклеточного рака легкого.
10. Комбинация одного и более эпотилонов и одного и более аналогов нуклеозидов для раздельного, одновременного или последовательного применения для лечения гиперпролиферативных заболеваний.
11. Комбинация по п. 10, в которой эпотилон выбирают из группы, состоящей из эпотилона B, эпотилона D, 21-гидроксиэпотилона B, 21-гидроксиэпотилона D, 21-аминоэпотилона B, 21-аминоэпотилона D, азаэпотилона B, азаэпотилона D, 9,10-дегидроэпотилона B, 9,10-дегидроэпотилона D, 26-трифтор-9,10-дегидроэпотилона B и 26-трифтор-9,10-дегидроэпотилона D.
12. Комбинация по п. 10, в которой аналог нуклеозида выбирают из группы, состоящей из азацитидина, кладрибина, цитарабина, флоксуридина, флударабина фосфата, 5-фторурацила, гемцитабина, пентостатина, урамустина и 5'-дезокси-5-фтор-N-[(пентилокси)карбонил]-цитидина.
13. Комбинация по п. 10, в которой эпотилоном является эпотилон D и аналог нуклеозида выбирают из группы, состоящей из 5-фторурацила и 5'-дезокси-5-фтор-N-[(пентилокси)карбонил]-цитидина.
14. Комбинация по п. 10, в которой гиперпролиферативное заболевание является злокачественной опухолью, выбранной из группы, состоящей из рака толстой кишки, рака молочной железы и немелкоклеточного рака легкого.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41753502P | 2002-10-09 | 2002-10-09 | |
| US60/417,535 | 2002-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005114018A true RU2005114018A (ru) | 2006-01-20 |
Family
ID=32094033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005114018/14A RU2005114018A (ru) | 2002-10-09 | 2003-10-09 | Эпотилон d+фторурацил/гемцитабин |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20040167097A1 (ru) |
| EP (1) | EP1551378A4 (ru) |
| JP (1) | JP2006504745A (ru) |
| KR (1) | KR20050051688A (ru) |
| CN (1) | CN1297258C (ru) |
| AU (1) | AU2003279923A1 (ru) |
| BR (1) | BR0315169A (ru) |
| CA (1) | CA2499682A1 (ru) |
| MX (1) | MXPA05003706A (ru) |
| RU (1) | RU2005114018A (ru) |
| WO (1) | WO2004032872A2 (ru) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| JP4791183B2 (ja) | 2002-08-23 | 2011-10-12 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロン、その中間体、類似体の合成およびその使用 |
| JPWO2004080462A1 (ja) | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | ｃ−Ｋｉｔキナーゼ阻害剤 |
| CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| US20050215604A1 (en) * | 2004-03-26 | 2005-09-29 | Kosan Biosciences, Inc. | Combination therapies with epothilones and carboplatin |
| EP1797881B1 (en) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
| EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
| EP2036557B1 (en) | 2006-05-18 | 2015-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
| EP2116246A1 (en) | 2007-01-19 | 2009-11-11 | Eisai R&D Management Co., Ltd. | Composition for treatment of pancreatic cancer |
| JP5319306B2 (ja) | 2007-01-29 | 2013-10-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌治療用組成物 |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| AU2011255647A1 (en) | 2010-05-18 | 2012-11-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| BR112015009004A8 (pt) | 2012-12-21 | 2021-07-20 | Eisai R&D Man Co Ltd | forma amorfa de derivado de quinolina e método de produção da mesma |
| MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
| HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
| CN107427505A (zh) | 2015-02-25 | 2017-12-01 | 卫材R&D管理有限公司 | 用于抑制喹啉衍生物的苦味的方法 |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
| CN107041886A (zh) | 2016-02-06 | 2017-08-15 | 北京华昊中天生物技术有限公司 | 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU756699B2 (en) * | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6596875B2 (en) * | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
| AU771089B2 (en) * | 1999-02-22 | 2004-03-11 | Bristol-Myers Squibb Company | C-21 modified epothilones |
| US6291684B1 (en) * | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
| EP1181013B1 (en) * | 1999-04-14 | 2006-10-11 | Dana-Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
| US6489314B1 (en) * | 2001-04-03 | 2002-12-03 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| WO2002072085A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
| MXPA04006822A (es) * | 2002-01-14 | 2004-12-08 | Novartis Ag | Combinaciones que comprenden epotilonas y anti-metabolitos. |
-
2003
- 2003-10-09 CA CA002499682A patent/CA2499682A1/en not_active Abandoned
- 2003-10-09 AU AU2003279923A patent/AU2003279923A1/en not_active Abandoned
- 2003-10-09 JP JP2004543655A patent/JP2006504745A/ja active Pending
- 2003-10-09 WO PCT/US2003/032148 patent/WO2004032872A2/en active Application Filing
- 2003-10-09 BR BR0315169-7A patent/BR0315169A/pt not_active Withdrawn
- 2003-10-09 MX MXPA05003706A patent/MXPA05003706A/es not_active Application Discontinuation
- 2003-10-09 CN CNB2003801009323A patent/CN1297258C/zh not_active Expired - Fee Related
- 2003-10-09 EP EP03773239A patent/EP1551378A4/en not_active Withdrawn
- 2003-10-09 KR KR1020057006143A patent/KR20050051688A/ko not_active Application Discontinuation
- 2003-10-09 RU RU2005114018/14A patent/RU2005114018A/ru not_active Application Discontinuation
-
2004
- 2004-05-03 US US10/683,203 patent/US20040167097A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003279923A1 (en) | 2004-05-04 |
| CN1297258C (zh) | 2007-01-31 |
| EP1551378A4 (en) | 2006-09-06 |
| WO2004032872A2 (en) | 2004-04-22 |
| CN1703208A (zh) | 2005-11-30 |
| WO2004032872A3 (en) | 2004-11-11 |
| MXPA05003706A (es) | 2005-07-01 |
| KR20050051688A (ko) | 2005-06-01 |
| CA2499682A1 (en) | 2004-04-22 |
| JP2006504745A (ja) | 2006-02-09 |
| BR0315169A (pt) | 2005-08-23 |
| EP1551378A2 (en) | 2005-07-13 |
| US20040167097A1 (en) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005114018A (ru) | Эпотилон d+фторурацил/гемцитабин | |
| JP2006504745A5 (ru) | ||
| CN1753665A (zh) | 作为红细胞生成刺激剂的中链长脂肪酸类、甘油酯类和类似物 | |
| RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
| JP2006507308A5 (ru) | ||
| RU2007145489A (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
| RU2006131553A (ru) | Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap | |
| CA2503730A1 (en) | Cytarabine monophosphate prodrugs | |
| RU2004119854A (ru) | Способы терапии | |
| HU213677B (en) | Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them | |
| RU2005126819A (ru) | Усовершенствованное лечение опухолей | |
| Dummer et al. | A Rational Approach to the Therapy of Cutaneous T–Cell Lymphomas | |
| JP2001509479A (ja) | ヌクレオチド含有組成物 | |
| BR9807473A (pt) | Tratamentos de doença relacionados à citocina | |
| Splinter et al. | Phase I study of alpha-difluoromethylornithine and methyl-GAG | |
| CA1299102C (en) | Insulin potentiation therapy | |
| Sierocki et al. | Small cell carcinoma of the lung experience with a six‐drug regimen | |
| Burzynski et al. | Phase I clinical studies of antineoplaston A5 injections | |
| CN1110139A (zh) | 丹酚酸a用于治疗肿瘤新用途 | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| Teicher | Combination of perfluorochemical emulsions and carbogen breathing with cancer chemotherapy | |
| Salazar et al. | Theoretical and practical uses of elective systemic (half-body) irradiation after 20 years of experimental designs | |
| JP2010155861A (ja) | 末梢神経系の疾患の治療のためのピリミジンヌクレオチドの使用 | |
| CN113116900B (zh) | 一类核苷类似物在制备预防和/或治疗脑血管疾病药物中的应用 | |
| McNamee | Fast-track publication at The Lancet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090120 |